Millendo Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Millendo Therapeutics generated cash of -$30,435,000, which is more than the previous year. Cash used in financing activities reached the amount of $5,386,000 last year. Net change in cash is therefore -$24,854,000.
Cash Flow
| 2012 | -11.15M | -17.64M | 39.03M |
|---|---|---|---|
| 2013 | -18.09M | -11.01M | 32.41M |
| 2014 | -30.58M | -32.78M | 51.71M |
| 2015 | -50.28M | -38.29M | 125.38M |
| 2016 | -61.73M | 8.29M | 54.14M |
| 2017 | -45.55M | 17.32M | 0 |
| 2018 | -23.64M | 1.93M | 77.74M |
| 2019 | -41.22M | 3.98M | 26.94M |
| 2020 | -30.43M | -26K | 5.38M |
MLND Cash Flow Statement (2012 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 63.51M | 73.77M | 17.62M | 43.93M | 43.22M | 6.41M | 18.07M | 14.77M | 4.54M |
Operating activities | |||||||||
Net income | -36.40M | -44.56M | -27.19M | -50.97M | -82.26M | -73.21M | -49.52M | -29.04M | -13.51M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.10M | 1.05M | 32K | 1.65M | 2.23M | 1.28M | 450K | 231K | 93K |
Stock-based compensation expense | 4.24M | 4.31M | 1.42M | 6.89M | 9.21M | 19.33M | 12.40M | 5.09M | 1.38M |
| Deferred income tax benefit | 4.24M | 4.31M | 1.42M | 6.89M | 9.21M | 19.33M | 12.40M | 5.09M | 1.38M |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 25K | -469K | 320K | 68K | -1.17M | -171K | 2.31M | -721K | 599K |
Cash generated by operating activities | -30.43M | -41.22M | -23.64M | -45.55M | -61.73M | -50.28M | -30.58M | -18.09M | -11.15M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | -68.85M | -82.67M | -95.22M | -57.60M | -15.97M | -16.69M |
Investments In Property Plant And Equipment | -26K | -397K | -36K | -158K | -2.58M | -5.22M | -2.80M | -719K | -849K |
Acquisitions Net | 0 | 0 | -524K | -1.1M | -1.75M | -1.5M | -1.5M | 0 | 0 |
Cash generated by investing activities | -26K | 3.98M | 1.93M | 17.32M | 8.29M | -38.29M | -32.78M | -11.01M | -17.64M |
Financing activities | |||||||||
Common Stock Issued | 5.45M | 26.67M | 38.75M | 0 | 53.92M | 124.06M | 51.73M | 32.41M | 4.03M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -145K | 0 | -169K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 5.38M | 26.94M | 77.74M | 0 | 54.14M | 125.38M | 51.71M | 32.41M | 39.03M |
Net Change In Cash | -24.85M | -10.25M | 56.14M | -28.22M | 706K | 36.81M | -11.66M | 3.30M | 10.23M |
Cash at end of period | 38.65M | 63.51M | 73.77M | 15.70M | 43.93M | 43.22M | 6.41M | 18.07M | 14.77M |
| Data source |